News Center

Discover all of the trending news of the Ipsen Group


133 results

Oncology

Ipsen’s partner Exelixis announces U.S. FDA approval o...

RCC is the most common form of kidney cancer in adults. The FDA’s priority…

Group

Ipsen announces its corporate agenda for 2018

15 February 2018: Full year 2017 sales & results 26 April 2018: First quarter 2018…

Financial information

Ipsen delivers strong sales growth of 22.6% for the third qu...

Paris (France), 26 October 2017 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical…

Group

Agreement signed for the creation of an Algerian-French join...

This took place during the meeting of the Algerian-French high-level intergovernmental Committee (CIHN), at the…

People

Dr James A. Levine appointed President of the Fondation IPSE...

"I am delighted to accept the Presidency of the Fondation IPSEN which plays an…

Event

Ipsen to Present at the Citi 2017 Global Healthcare Conferen...

David Meek, CEO will present at the Citi 2017 Global Healthcare Conference in New York…

Neuroscience

Ipsen supports awareness of Neuroendocrine Tumors (NET) and ...

NET Cancer Day, a global initiative of the International Neuroendocrine Cancer Alliance (INCA) and…

Rare diseases

Ipsen launches acromunity.com a website designed with patien...

Acromunity.com is intended for patients who have just been diagnosed or patients…

People

Dr Sotirios Stergiopoulos appointed as the new President of ...

Dr Sotirios Stergiopoulos, Senior Vice-President & Head of Global Medical Affairs at Ipsen Bioscience, has…

Event

Ipsen at ESMO 2017

Want to know more about the activities Ipsen is organising and data we are sharing…

Financial information

Ipsen’s First Half 2017 Financial Results

Financial Community: audio broadcast will start at 04:00 CEST Click here to access audio webcast…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021